护理学报 ›› 2024, Vol. 31 ›› Issue (13): 45-49.doi: 10.16460/j.issn1008-9969.2024.13.045
肝癌靶向药物相关手足皮肤反应的护理研究进展
吴舒1a,2, 张培培2, 占正寅1b, 宁艳婷1c, 夏娟1a, 陈敬芳2,3, 罗芳洲1a
- 1.国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院深圳医院 a.ICU;b.肝胆外科;c.护理部,深圳 518116;
2.南华大学 护理学院,湖南 衡阳 421001;
3.国家感染性疾病临床医学研究中心/深圳市第三人民医院 科研教学部,深圳 518112
摘要： 目的 综述国内外肝癌靶向药物相关手足皮肤反应的临床研究进展,旨在为临床护理提供参考。方法 检索国内外相关文献,对肝癌靶向药物相关手足皮肤反应护理评估、影响因素、护理措施等进行归纳。结果 注意区分化疗药和靶向药引起的手足皮肤反应的症状;常用的护理评估工具有3个标准、3个质量评价量表;主要影响因素包括人口学资料、部位和药物等;护理要点包括：西医外用药护理、中医外用技术的应用及护理,护理重点是做好居家发生手足皮肤反应的前、中、后的健康教育和症状护理。结论 中西医护理有助于预防和治疗靶向药相关的手足皮肤反应,但仍存在护理评估工具、最佳证据和标准流程的缺乏等问题,未来研究应在整合最佳证据,构建临床指南,评估工具开发,多学科合作形成系统化的护理方案等方面深入探索。
中图分类号:
- R473.73
| [1] 冯钰,黄振,孙永琨,等.肝癌患者常见药物治疗相关不良反应互联网管理专家指导意见[J].肝癌电子杂志,2021,8(2):16-22. [2] Lin SM, Lu SN, Chen PT, et al.HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma[J]. Hepatol Int,2017,11(2):199-208.DOI:10.1007/s12072-016-9774-x. [3] Chu D, Lacouture ME, Fillos T, et al.Risk of Hand-Foot Skin Reaction with sorafenib:a systematic review and Meta-analysis[J].Acta Oncol, 2008,47(2):176-186.DOI:10.1080/02841860701765675. [4] Zhao Y, Liu W, Zheng L, et al.Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis[J]. J Gastrointest Oncol,2023,14(6):2536-2548. DOI:10.21037/jgo-23-651. [5] Yamashita T, Kudo M, Ikeda K, et al.REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset[J]. J Gastroenterol, 2020,55(1):113-122. DOI:10.1007/s00535-019-01642-1. [6] Xie Y, Wu H, He Y, et al.Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer[J]. Cell Death Dis, 2024, 15(2):110.DOI:10.1038/s41419-024-06493-0. [7] Chanprapaph K, Rutnin S, Vachiramon V.Multikinase inhibitor-induced Hand-Foot Skin Reaction: a review of clinical presentation, pathogenesis, and management[J]. Am J Clin Dermatol, 2016,17(4):387-402.DOI:10.1007/s40257-016-0197-1. [8] Komatsu H, Yagasaki K, Hirata K, et al.Unmet needs of cancer patients with chemotherapy-related Hand-Foot Syndrome and targeted therapy-related Hand-Foot Skin Reaction: a qualitative study[J].Eur J Oncol Nurs,2019,38:65-69. DOI:10.1016/j.ejon.2018.12.001. [9] Takayasu K, Arii S, Ikai I, et al.Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients[J]. Gastroenterology,2006,131(2):461-469. DOI:10.1053/j.gastro.2006.05.021. [10] Ogasawara S, Kanai F, Obi S, et al.Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma[J]. Hepatol Int,2011, 5(3):850-856. DOI:10.1007/s12072-010-9249-4. [11] 周晨,刘家成,石钦,等. 肝癌分子靶向药物及免疫抑制剂治疗的研究现状及进展[J].中华介入放射学电子杂志,2019,7(3):243-250. [12] Sato-Sano M,Cury-Martins J,Macarenco R,et al.Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib[J]. J Dtsch Dermatol Ges,2018,16(12):1486-1489.DOI:10.1111/ddg.13704 . [13] Williams LA, Ginex PK, Ebanks gL Jr, et al. ONS Guidelines for cancer treatment-related skin toxicity[J]. Oncol Nurs Forum, 2020, 47(5):539-556. DOI:10.1188/20.ONF.539-556. [14] Braghiroli CS, Ieiri R, Ocanha JP,et al.Do you know this syndrome? Hand-Foot Syndrome[J].An Bras Dermatol,2017,92(1):131-133. DOI:10.1590/abd1806-4841.20174602. [15] Blum JL, Jones SE, Buzdar AU, et al.Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer[J]. J Clin Oncol,1999,17(2):485-493. DOI:10.1200/JCO.1999.17.2.485. [16] Sibaud V, Dalenc F, Chevreau C, et al.HFS-14, a specific quality of life scale developed for patients suffering from Hand-Foot Syndrome[J]. Oncologist, 2011, 16(10):1469-1478. DOI:10.1634/theoncologist.2011-0033. [17] Anderson RT, Keating KN, Doll HA, et al.The Hand-Foot Skin Reaction and Quality of Life Questionnaire: an assessment tool for oncology[J].Oncologist, 2015,20(7):831-838. DOI:10.1634/theoncologist.2014-0219. [18] 于然, 娄彦妮, 贾立群. 手足皮肤反应患者生活质量量表汉化及信效度分析[J].中国中西医结合皮肤性病学杂志, 2020, 19(2):142-144. [19] Finlay AY,Khan GK.Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use[J]. Clin Exp Dermatol, 1994, 19(3):210-216. DOI:10.1111/j.1365-2230.1994.tb01167.x. [20] 赵德华,王继生,楚明明,等.抗肿瘤药物引起手足综合征的机制及防治措施[J].中国现代应用药学, 2019, 36(11):1437-1442.DOI:10.13748/j.cnki.issn1007-7693.2019.11.026. [21] Nikolaou V, Syrigos K, Saif MW.Incidence and implications of chemotherapy related hand-foot syndrome[J]. Expert Opin Drug Saf, 2016,15(12):1625-1633. DOI:10.1080/14740338.2016.1238067. [22] Yoshino T, Komatsu Y, Yamada Y,et al.Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations[J]. Invest New Drugs,2015,33(3):740-750. DOI:10.1007/s10637-014-0154-x. [23] 李苗,朱映霞,段相会.卡瑞利珠单抗联合甲磺酸阿帕替尼、替吉奥治疗中晚期原发性肝癌的临床观察[J].中国医药指南, 2023, 21(22):22-25.DOI:10.15912/j.cnki.gocm.2023.22.009. [24] Belum VR, Wu S, Lacouture ME.Risk of Hand-Foot Skin Reaction with the novel multikinase inhibitor regorafenib: a Meta-analysis[J]. Invest New Drugs, 2013, 31(4):1078-1086. DOI:10.1007/s10637-013-9977-0. [25] Belum VR, Serna-Tamayo C, Wu S, et al.Incidence and risk of Hand-Foot Skin Reaction with cabozantinib, a novel multikinase inhibitor: a Meta-analysis[J]. Clin Exp Dermatol,2016,41(1):8-15. DOI:10.1111/ced.12694. [26] Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced Hand-Foot Syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management[J]. J Am Acad Dermatol,2014,71(4):787-794. DOI:10.1016/j.jaad.2014.03.019. [27] Nonomiya Y,Yokokawa T, Kawakami K, et al.Regorafenib-induced Hand-Foot Skin Reaction is more severe on the feet than on the hands[J]. Oncol Res, 2019, 27(5):551-556. DOI:10.3727/096504018X15291727589740. [28] Mahon SM, Carr E.Skin toxicities: common side effect[J]. Clin J Oncol Nurs,2021,25(6):32. DOI:10.1188/21.CJON.S2.32. [29] Lacouture ME.Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer[J]. Cancer Nurs,2007,30(4 Suppl 1):S17-S26. DOI:10.1097/01.NCC.0000281758.85704.9b. [30] Székely H, Tóth LM, Rancz A, et al.Anti-tumor necrosis factor alpha versus corticosteroids: a 3-fold difference in the occurrence of venous thromboembolism in inflammatory bowel disease-a systematic review and Meta-analysis[J]. J Crohns Colitis,2024,18(5):773-783.DOI:10.1093/ecco-jcc/jjad193. [31] Lien RY, Tung HH, Wu SL,et al.Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: a randomised experiment study[J]. Cancer Rep (Hoboken),2022,5(7):e1532.DOI:10.1002/cnr2.1532. [32] 王容,王超,孙雪蓉,等.硅基修复材料在靶向药物治疗肠道恶性肿瘤病人并发皮肤毒性反应中的应用[J].循证护理,2021,7(7):987-989. [33] 杨渺. 盐酸多柔比星脂质体引起手足综合征的护理[J]. 中国社区医师, 2020, 36(2):149-150. [34] 童竹月, 王彬彬. 手足综合征的最新研究进展[J]. 浙江临床医学, 2017, 19(3): 581-583. [35] Qiu J, Chen M, Liu J, et al.The skin-depigmenting potential of Paeonia lactiflora root extract and paeoniflorin: in vitro evaluation using reconstructed pigmented human epidermis[J]. Int J Cosmet Sci,2016,38(5):444-451. DOI:10.1111/ics.12309. [36] 邓博,彭艳梅,崔慧娟,等.外用中药防治靶向药物皮肤毒性反应的网络药理分析[J].中华中医药学刊, 2019,37(5):1054-1057.DOI:10.13193/j.issn.1673-7717.2019.05.007. [37] Pei JP, Fan LH, Nan K, et al.HSYA alleviates secondary neuronal death through attenuating oxidative stress, inflammatory response, and neural apoptosis in SD rat spinal cord compression injury[J]. J Neuroinflammation, 2017,14(1):97.DOI:10.1186/s12974-017-0870-1. [38] 周琴,周国芳,董良,等.中药熏洗治疗抗肿瘤靶向药相关性手足综合征临床观察[J].浙江中医杂志,2020,55(6):431-432.DOI:10.13633/j.cnki.zjtcm.2020.06.026. [39] 陈佳露, 邵田娱, 张瑶,等. 中药手足宁方外用治疗阿帕替尼所致3级手足皮肤反应的临床研究[J]. 中国中西医结合杂志, 2023, 43(3):298-302. [40] Yu R, Wu X, Jia L, et al.Effect of Chinese herbal compound lc09 on patients with capecitabine-associated Hand-Foot Syndrome: a randomized, double-blind, and parallel-controlled trial[J].Integr Cancer Ther,2020,19:1534735420928466.DOI:10.1177/1534735420928466. [41] 中国中医药信息学会外治分会.中药熏洗(浴)疗法临床外用技术规范(草案)[J]. 中国实验方剂学杂志, 2020,26(9):85-89. DOI:10.13422/j.cnki.syfjx.20200153. [42] 江晓林,杨镇洲.金银花液湿敷治疗西妥昔单抗致痤疮样皮疹的效果观察[J].中国药房,2015,26(2):243-244. [43] 覃霄燕,李鸿章,王海存,等.五味消毒饮熏洗联合心理疏导综合干预阿帕替尼后手足综合征(热毒壅盛)随机平行对照研究[J].实用中医内科杂志,2018,32(8):24-28.DOI:10.13729/j.issn.1671-7813.z20180195. [44] 朱孝娟. 参草手足润肤膏治疗抗肿瘤药物引起手足综合征的随机双盲对照研究[D].北京:中国中医科学院,2015. [45] Andayani Y.Efficacy of Extra Virgin Olive Oil(EVOO) Supplementation on Serum COX-2, Malondialdehyde, TNF-alpha,Hand-Foot Syndrome incidence in patients with capecitabine: NCT06188000[R]. clinicaltrials.gov, 2024[2024-01-01].https://clinicaltrials.gov/study/NCT06188000. [46] Jessa Hospital.Evaluating the effectiveness of photobiomodulation therapy in the management of Hand-Foot Syndrome and Hand-Foot Skin Reaction:a single-arm trial: NCT04979078[R].[2024-01-01].https://clinicaltrials.gov/study/NCT04979078. [47] Chen J, Wang Z.How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs[J]. J Oncol Pharm Pract, 2021, 27(4):919-929.DOI:10.1177/10781552211009291. [48] Ding J, Farah MH, Nayfeh T, et al.Targeted therapy- and chemotherapy-associated skin toxicities: systematic review and Meta-analysis[J]. Oncol Nurs Forum, 2020, 47(5):E149-E160. DOI:10.1188/20.ONF.E149-E160. |
| [1] | 贺芳, 温秀兰, 林艳, 孙黎, 王晓杰, 余欣, 刘会, 郭晓萍, 周艳. 基于移动医疗的新生儿护理线上咨询门诊的建立与实施[J]. 护理学报, 2024, 31(9): 20-23. |
| [2] | 方雅婷, 王岩, 王哲芸, 余云, 徐婷婷. 经口气管插管患者口腔功能减退的研究进展[J]. 护理学报, 2024, 31(9): 28-31. |
| [3] | 陈洁, 孟庆童, 刘惊今, 吴艳妮. 基于指南的慢性心力衰竭患者运动康复科普手册研制[J]. 护理学报, 2024, 31(9): 36-41. |
| [4] | 符路路, 解艺璇, 王玥, 魏巍, 张传英, 朱宇. 新生儿操作性疼痛听觉刺激干预的证据总结[J]. 护理学报, 2024, 31(9): 42-47. |
| [5] | 陈杰, 赖静, 王城阅, 徐良英, 晏娟, 罗雪. 基于三维质量结构理论的ICU护理人文关怀质量评价指标体系的构建[J]. 护理学报, 2024, 31(9): 54-59. |
| [6] | 慕晓莹, 周芬, 樊英怡, 袁婷, 王玉玺, 吕云鹏, 荣红国. 基于离散选择实验的“互联网+手法排乳”患者偏好研究[J]. 护理学报, 2024, 31(9): 72-78. |
| [7] | 何娇, 刘义兰, 官春燕, 韩燕红, 陈睿, 胡德英. 基于泰勒原理的医院护理人文关怀培训课程体系的构建[J]. 护理学报, 2024, 31(8): 13-17. |
| [8] | 陆国涛, 马子雪, 张芳, 周航, 徐静艳, 杨红丽. 叙事治疗文件在叙事护理中的应用及展望[J]. 护理学报, 2024, 31(8): 23-26. |
| [9] | 陈思齐, 刘宁, 侯晓敏, 卢舒颖. 机器人胃癌手术围术期加速康复外科护理的最佳证据总结[J]. 护理学报, 2024, 31(8): 31-36. |
| [10] | 纪锐婷, 林丹娜, 刘小成, 李婷婷, 谢映梅, 胡冰, 应文娟. 早产儿初乳口腔免疫疗法的最佳证据总结[J]. 护理学报, 2024, 31(8): 37-42. |
| [11] | 张小莉, 杨鑫玉, 肖宇, 刘春燕, 张璐, 伍晓琴, 黄月霖, 傅静. 晚期癌症患者代理决策者安宁疗护决策后悔研究的范围综述[J]. 护理学报, 2024, 31(8): 49-54. |
| [12] | 莫然, 常晓未, 马芳芳, 顾晴. 18例肿瘤患者并发危重度免疫检查点抑制剂相关心肌炎的护理[J]. 护理学报, 2024, 31(8): 60-62. |
| [13] | 白雅萍, 施婧. 共享决策在心脏瓣膜病介入治疗患者中的应用研究进展[J]. 护理学报, 2024, 31(7): 32-35. |
| [14] | 周毅峰, 杨继平, 胡正中, 袁浩. 肝癌切除手术患者目标导向性血糖监测的证据总结[J]. 护理学报, 2024, 31(7): 46-50. |
| [15] | 倪乐凤, 刘林, 沈春华, 乔瑶, 周亮, 朱强, 龚卫娟. 输血护理时限管理相关指南的质量评价及内容分析[J]. 护理学报, 2024, 31(7): 51-56. |
|
||